This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Mark Your Calendar for Next Year's Event!
May 9-12, 2022Hynes Convention Center, Boston

Andrew Bellinger, M.D., Ph.D.
Chief Scientific Officer at Verve Therapeutics

Profile

Andrew Bellinger is the chief scientific officer of Verve Therapeutics. He specializes in company creation and growth, building high performing R&D teams, translational medicine, drug delivery, and has a particular interest in the clinical development of novel classes of therapies. He is a cardiologist at Brigham and Women’s Hospital and is board-certified in cardiovascular medicine and internal medicine. He is also a co-founder of Corner Therapeutics.  Prior to joining Verve, Dr. Bellinger co-founded and served as chief scientific officer of Lyndra Therapeutics, and prior to that as the chief scientific officer of Cocoon Biotech. Dr. Bellinger completed his clinical training in internal medicine at the University of California, San Francisco, and his clinical training in cardiology at Brigham and Women’s Hospital. He completed his postdoctoral research training in drug delivery with Dr. Robert Langer at the Massachusetts Institute of Technology. Dr. Bellinger holds an M.D., a Ph.D., and an MPhil from Columbia University, an M.S. in mathematics from New York University, and an A.B. in physics from Princeton University.

Agenda Sessions

  • ROOM 205C: In vivo CRISPR Base Editing of PCSK9 Durably Lowers Cholesterol in Primates

    9:30am